glp 1 drugs for weight loss reviews 2024 in Review: The Rise of GLP-1 Medications GLP-1 Medications for Weight Loss:

(2024) 36:13043.e5

Genmabs bet on Merus will be a key case study as petosemtamabs clinical readouts unfold

Hepatic Safety Hepatic safety has been a particular focus of attention for orforglipron given the hepatotoxicity findings that led to the discontinuation of two competing oral small-molecule GLP-1 programs

doi: 10.1073/pnas.94.13.6646

Since its US FDA approval in June 2021 and subsequent EU and Japan approval in 2022 and 2023, respectively, for chronic weight management, WEGOVY has rapidly gained traction

NCT04255433) is expected to provide definitive answers on the impact of tirzepatide on cardiovascular disease compared with dulaglutide, a long-acting GLP-1 RA that has been shown to be cardioprotective in individuals with type 2 diabetes at increased cardiovascular risk [31]